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control study. Annual hospitalisation costs of benzodi-
azepine related fall injuries were based on the age-speciﬁc
PARs and extrapolated to the European population using
European data on accidents and demographic data of the
EU. RESULTS: Fall injuries were signiﬁcantly associated
with benzodiazepine use (OR 1.6, CI 95% 1.4–1.7), espe-
cially in the age over 85 years (OR 3.6, CI 95% 2.9–4.5).
The total annual admission costs in 2000 of fall related
injuries attributable to benzodiazepine use were €1.8
billion (95% CI €1.5–2.2 billion) in the EU. CONCLU-
SIONS: The estimated costs of hospitalisations of fall
injuries related to benzodiazepine use in the EU varied
between €1.5 and €2.2 billion each year. More than 90%
of these costs were related to accidental falls in the elderly,
with hip fractures as the major contributor. Discontinua-
tion of prescribing of benzodiazepines or substituting
benzodiazepines with other drugs not associated with the
risk of falls to the elderly will to a large extent prevent
these accidents.
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OBJECTIVES: Osteoporosis mainly concerns post-
menopausal women, may cause fractures and can be
treated. The diagnosis of osteoporosis covers the evalua-
tion of bone density. Gold standard still is the dual x-ray
absorptiometry (DXA) but the qualitative ultrasound
(QUS) as a non-invasive and radiation-free technology is
becoming more important. This rapid health economic
health technology assessment (HTA) examines the cost-
effectiveness of QUS as a technique for screening and
diagnosing osteoporosis and subsequently for the pre-
vention of osteoporotic fractures. METHODS: Accord-
ing to the methodological recommendations for rapid
health economic HTA in Germany a systematic literature
search was conducted. Quantitative and qualitative infor-
mation synthesis was done. The incremental cost-
effectiveness of a two-step proceeding (QUS for all
women as a ﬁrst step; in case of a positive QUS-test a
DXA is performed as a second step) compared to a one-
step proceeding (all women get an examination with
DXA) as well as a comparison of the one step proceed-
ing QUS alone versus DXA alone was calculated by the
authors. RESULTS: Four publications dealt with the
question of the cost-effectiveness of QUS as a screening
instrument in a two-step proceeding. Despite the method-
ological weaknesses of the studies the reported cost could
be used in the calculation of the incremental cost-
effectiveness ratio. Depending on the considered studies
a two-step proceeding is cost-effective as long as the costs
of one QUS examination lie between 31% and 51% of
costs of an examination with DXA. One diagnosed case
in DXA rise additional €1000 compared to QUS. It has
to be considered that QUS shows a higher amount of false
positive cases that subsequently will increase costs. CON-
CLUSION: A priorisation of a two-step or a one-step pro-
ceeding is not possible at present due to the missing data
and the lack of evidence. Decision analytic models con-
sidering long-term effects are recommended.
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OBJECTIVES: To evaluate the cost-effectiveness of all
recommended therapies for prevention of osteoporotic
hip, spine, and wrist fractures in postmenopausal women
without prior fracture. METHODS: A retrospective,
modeled cost-effectiveness analysis of all therapies given
in the international guidelines for osteoporosis treatment
and prevention of fractures and currently available on the
Slovenian market was performed from societal per-
spective. The analysis included postmenopausal women
divided in three age groups treated by the following treat-
ment options: no drug therapy, alendronate, etidronate,
calcitonin, hormone replacement therapy (HRT) and
raloxifene. Data on clinical efﬁcacy of all therapies in
terms of decreasing fracture risk (relative risks for hip,
spine and wrist fracture) were pooled from the published
summarized systematic reviews of meta-analyses obtained
by Medline search. A Markov model of 10-years preven-
tive treatment for women without previous fracture was
developed with DATA 4.0 decision analysis software.
Model data on baseline fracture and death probabilities
were obtained from National Health care Institute 2000
Report. Cost estimates on annual drug treatment and
fracture treatment were derived from Slovenian sources
(2002 price list) and converted to Euros. Utility values for
the health states deﬁned in the model were obtained from
the reference literature. RESULTS: The incremental cost-
effectiveness ratio for 10 years of HRT treatment versus
no therapy ranged from €174088/QALY at age 65-years
to €65578/QALY for 75-years and to only €480/QALY at
age 85-years, respectively. The incremental cost-effective-
ness ratio for 10 years of treatment with alendronate
versus no therapy ranged from €183258/QALY at age 
65-years to €68457/QALY for 75-years and to only
€2291/QALY for age 85-years, respectively. Etidronate,
raloxifene, and calcitonin were dominated by either HRT
or alendronate for all age groups. CONCLUSIONS: HRT
and alendronate can be considered as cost-effective ther-
apies for prevention of osteoporotic fractures in older
postmenopausal women without prior fracture.
